Organogenesis Hldgs Inc Financials

ORGO

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Organogenesis Hldgs Inc (ORGO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 41/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Organogenesis Hldgs Inc has an operating margin of -0.3%, meaning the company retains $-0 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from 2.9% the prior year.

Growth

Organogenesis Hldgs Inc's revenue grew 11.3% year-over-year to $482.0M, a solid pace of expansion. This earns a growth score of 61/100.

Leverage

Organogenesis Hldgs Inc carries a low D/E ratio of 0.89, meaning only $0.89 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 78/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 3.69, Organogenesis Hldgs Inc holds $3.69 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Organogenesis Hldgs Inc generated $14.2M in operating cash flow, capex of $10.0M consumed most of it, leaving $4.2M in free cash flow. This results in a low score of 4/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Organogenesis Hldgs Inc generates a 0.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 1/100. This is down from 1.8% the prior year.

Piotroski F-Score Strong

8/9

Organogenesis Hldgs Inc passes 8 of 9 financial strength tests. 3 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

16.50x

For every $1 of reported earnings, Organogenesis Hldgs Inc generates $16.50 in operating cash flow ($14.2M OCF vs $861K net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

-0.8x

Organogenesis Hldgs Inc earns $-0.8 in operating income for every $1 of interest expense (-$1.3M vs $1.5M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

$482.0M

YoY+11.3%

5Y CAGR+13.1%

Organogenesis Hldgs Inc generated $482.0M in revenue in fiscal year 2024. This represents an increase of 11.3% from the prior year.

EBITDA

$12.3M

YoY-46.3%

Organogenesis Hldgs Inc's EBITDA was $12.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 46.3% from the prior year.

Free Cash Flow

$4.2M

YoY-36.3%

Organogenesis Hldgs Inc generated $4.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 36.3% from the prior year.

Net Income

$861K

YoY-82.6%

Organogenesis Hldgs Inc reported $861K in net income in fiscal year 2024. This represents a decrease of 82.6% from the prior year.

EPS (Diluted)

$-0.01

YoY-125.0%

Organogenesis Hldgs Inc earned $-0.01 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 125.0% from the prior year.

Cash & Debt

$135.6M

YoY+30.6%

5Y CAGR+17.6%

Organogenesis Hldgs Inc held $135.6M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

126M

YoY-4.3%

5Y CAGR+3.7%

Organogenesis Hldgs Inc had 126M shares outstanding in fiscal year 2024. This represents a decrease of 4.3% from the prior year.

Gross Margin

76.0%

YoY+0.6pp

5Y CAGR+5.1pp

Organogenesis Hldgs Inc's gross margin was 76.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 0.6 percentage points from the prior year.

Operating Margin

-0.3%

YoY-3.2pp

5Y CAGR+11.2pp

Organogenesis Hldgs Inc's operating margin was -0.3% in fiscal year 2024, reflecting core business profitability. This is down 3.2 percentage points from the prior year.

Net Margin

0.2%

YoY-1.0pp

5Y CAGR+15.0pp

Organogenesis Hldgs Inc's net profit margin was 0.2% in fiscal year 2024, showing the share of revenue converted to profit. This is down 1.0 percentage points from the prior year.

Return on Equity

0.3%

YoY-1.4pp

Organogenesis Hldgs Inc's ROE was 0.3% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 1.4 percentage points from the prior year.

R&D Spending

$50.3M

YoY+13.3%

5Y CAGR+27.7%

Organogenesis Hldgs Inc invested $50.3M in research and development in fiscal year 2024. This represents an increase of 13.3% from the prior year.

Share Buybacks

$25.5M

Organogenesis Hldgs Inc spent $25.5M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$10.0M

YoY-58.8%

5Y CAGR+10.9%

Organogenesis Hldgs Inc invested $10.0M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 58.8% from the prior year.

ORGO Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$482.0M+11.3%	$433.1M-3.9%	$450.9M-3.5%	$467.4M+38.2%	$338.3M+29.6%	$261.0M
Cost of Revenue	$115.7M+8.7%	$106.5M+1.4%	$105.0M-8.0%	$114.2M+30.8%	$87.3M+15.0%	$75.9M
Gross Profit	$366.3M+12.1%	$326.7M-5.6%	$345.9M-2.1%	$353.2M+40.7%	$251.0M+35.6%	$185.0M
R&D Expenses	$50.3M+13.3%	$44.4M+11.6%	$39.8M+29.3%	$30.7M+53.1%	$20.1M+35.7%	$14.8M
SG&A Expenses	$294.5M+9.2%	$269.8M-5.0%	$283.8M+13.4%	$250.2M+22.5%	$204.2M+2.1%	$200.1M
Operating Income	-$1.3M-110.2%	$12.5M-43.8%	$22.3M-69.1%	$72.2M+170.5%	$26.7M+189.4%	-$29.9M
Interest Expense	$1.5M-29.5%	$2.2M+9.0%	$2.0M-72.2%	$7.2M-35.8%	$11.3M+25.4%	$9.0M
Income Tax	-$3.7M-167.3%	$5.4M+14.7%	$4.8M+115.3%	-$31.1M-5970.9%	$530K+253.3%	$150K
Net Income	$861K-82.6%	$4.9M-68.2%	$15.5M-83.5%	$94.2M+446.6%	$17.2M+144.5%	-$38.7M
EPS (Diluted)	$-0.01-125.0%	$0.04-66.7%	$0.12-82.9%	$0.70+366.7%	$0.15+135.7%	$-0.42

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$150.9M+49.4%	$101.0M+16.5%	$86.7M-31.6%	$126.7M-2.7%	$130.2M+18.4%	$110.0M+10.4%	$99.7M-8.2%	$108.5M
Cost of Revenue	N/A	N/A	$23.7M-23.6%	$31.1M+6.3%	$29.2M+1.7%	$28.7M+3.3%	$27.8M+7.7%	$25.8M
Gross Profit	N/A	N/A	$63.0M-34.1%	$95.6M-5.4%	$101.0M+24.3%	$81.3M+13.1%	$71.9M-13.1%	$82.7M
R&D Expenses	$13.2M+27.2%	$10.4M-2.3%	$10.6M-7.7%	$11.5M-26.0%	$15.6M+21.7%	$12.8M+8.8%	$11.8M+12.4%	$10.5M
SG&A Expenses	$79.7M+8.0%	$73.8M+1.8%	$72.5M-1.8%	$73.9M-3.5%	$76.5M+5.8%	$72.3M+17.8%	$61.4M-4.4%	$64.2M
Operating Income	$20.7M+264.8%	-$12.6M+53.0%	-$26.7M-361.7%	$10.2M+173.6%	-$13.9M-260.6%	-$3.9M-203.5%	-$1.3M-115.8%	$8.1M
Interest Expense	-$415K+38.0%	-$669K+30.4%	-$961K-1475.4%	-$61K-109.8%	$620K+20.6%	$514K+2.2%	$503K+13.3%	$444K
Income Tax	-$407K+83.3%	-$2.4M+64.8%	-$6.9M-369.0%	$2.6M+3.1%	$2.5M+211.6%	-$2.2M-82.7%	-$1.2M-127.5%	$4.5M
Net Income	$21.6M+329.6%	-$9.4M+50.2%	-$18.8M-345.6%	$7.7M+145.0%	-$17.0M-711.6%	-$2.1M-269.1%	-$569K-118.0%	$3.2M
EPS (Diluted)	$0.11+210.0%	$-0.10+41.2%	$-0.17-440.0%	$0.05+138.5%	$-0.13-550.0%	$-0.02	$0.00-100.0%	$0.02

ORGO Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$497.9M+8.2%	$460.0M+2.4%	$449.4M+1.4%	$443.3M+52.7%	$290.2M+31.5%	$220.7M
Current Assets	$285.9M+27.1%	$225.0M+1.1%	$222.6M-1.9%	$227.0M+30.2%	$174.3M+38.8%	$125.6M
Cash & Equivalents	$135.6M+30.6%	$103.8M+1.3%	$102.5M-10.1%	$113.9M+35.0%	$84.4M+39.8%	$60.4M
Inventory	$26.2M-7.2%	$28.3M+14.0%	$24.8M-1.0%	$25.0M-10.0%	$27.8M+21.3%	$22.9M
Accounts Receivable	$109.9M+34.0%	$82.0M-8.3%	$89.5M+8.5%	$82.5M+45.2%	$56.8M+44.3%	$39.4M
Goodwill	$28.8M0.0%	$28.8M0.0%	$28.8M0.0%	$28.8M0.0%	$28.8M+12.7%	$25.5M
Total Liabilities	$235.0M+29.6%	$181.4M-1.3%	$183.7M-9.0%	$201.9M+36.1%	$148.4M-10.1%	$165.1M
Current Liabilities	$77.5M-3.8%	$80.5M+7.3%	$75.0M-9.3%	$82.7M+21.2%	$68.2M+13.9%	$59.9M
Long-Term Debt	N/A	$66.6M-6.6%	$71.3M-3.8%	$74.1M+5.8%	$70.0M+41.0%	$49.6M
Total Equity	$262.9M-5.7%	$278.7M+4.9%	$265.7M+10.1%	$241.3M+70.2%	$141.8M+172.6%	$52.0M
Retained Earnings	-$40.1M+2.1%	-$41.0M+9.6%	-$45.3M+25.5%	-$60.8M+60.8%	-$155.0M+9.3%	-$171.0M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$509.8M+10.6%	$461.1M-1.3%	$467.4M-6.1%	$497.9M+12.3%	$443.2M-3.3%	$458.5M-0.3%	$460.0M-0.6%	$462.6M
Current Assets	$299.7M+15.2%	$260.2M-3.0%	$268.2M-6.2%	$285.9M+22.1%	$234.2M+3.1%	$227.2M+0.9%	$225.0M-0.2%	$225.6M
Cash & Equivalents	$63.7M-12.8%	$73.1M-33.5%	$110.0M-18.9%	$135.6M+50.8%	$89.9M+1.4%	$88.6M-14.7%	$103.8M+5.7%	$98.2M
Inventory	$39.6M+19.8%	$33.0M+12.6%	$29.3M+11.9%	$26.2M-2.5%	$26.9M-2.9%	$27.7M-2.0%	$28.3M+1.2%	$27.9M
Accounts Receivable	$168.8M+40.2%	$120.4M+16.5%	$103.3M-6.0%	$109.9M+3.7%	$105.9M+10.2%	$96.1M+17.3%	$82.0M-8.2%	$89.3M
Goodwill	$28.8M0.0%	$28.8M0.0%	$28.8M0.0%	$28.8M0.0%	$28.8M0.0%	$28.8M0.0%	$28.8M0.0%	$28.8M
Total Liabilities	$254.7M+11.8%	$227.9M+1.5%	$224.5M-4.5%	$235.0M+30.8%	$179.7M-0.4%	$180.5M-0.5%	$181.4M-2.4%	$185.8M
Current Liabilities	$90.3M+37.2%	$65.8M+1.2%	$65.1M-16.0%	$77.5M-9.6%	$85.7M+3.5%	$82.8M+2.8%	$80.5M-1.2%	$81.5M
Long-Term Debt	N/A	N/A	N/A	$62.3M-2.2%	$63.8M-2.2%	$65.2M-2.1%	$66.6M-2.1%	$68.0M
Total Equity	$255.1M+9.4%	$233.2M-4.0%	$242.9M-7.6%	$262.9M-0.2%	$263.5M-5.2%	$278.0M-0.2%	$278.7M+0.6%	$276.9M
Retained Earnings	-$46.8M+31.6%	-$68.3M-15.9%	-$59.0M-47.0%	-$40.1M+33.3%	-$60.1M-39.6%	-$43.1M-5.1%	-$41.0M-1.4%	-$40.4M

ORGO Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	$14.2M-54.0%	$30.9M+24.4%	$24.9M-59.9%	$62.0M+1033.9%	$5.5M+116.3%	-$33.5M
Capital Expenditures	$10.0M-58.8%	$24.4M-28.1%	$33.9M+8.6%	$31.2M+76.6%	$17.7M+195.4%	$6.0M
Free Cash Flow	$4.2M-36.3%	$6.6M+172.5%	-$9.0M-129.4%	$30.8M+351.9%	-$12.2M+69.1%	-$39.5M
Investing Cash Flow	-$10.0M+58.8%	-$24.4M+28.1%	-$33.9M-8.6%	-$31.2M-32.9%	-$23.5M-276.9%	-$6.2M
Financing Cash Flow	$27.6M+602.0%	-$5.5M-150.3%	-$2.2M-112.3%	-$1.0M-102.4%	$42.5M-46.1%	$78.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$25.5M	$0	$0	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	$3.1M+109.4%	-$32.9M-64.9%	-$19.9M-282.3%	$10.9M+130.8%	$4.7M+146.6%	-$10.2M-195.7%	$10.6M-36.6%	$16.7M
Capital Expenditures	$2.2M-38.6%	$3.6M+0.3%	$3.6M+7.9%	$3.4M+78.8%	$1.9M-15.4%	$2.2M-33.2%	$3.3M-44.4%	$6.0M
Free Cash Flow	$844K+102.3%	-$36.5M-55.0%	-$23.6M-411.0%	$7.6M+165.1%	$2.9M+123.1%	-$12.4M-269.9%	$7.3M-32.2%	$10.8M
Investing Cash Flow	-$2.2M+38.6%	-$3.6M-0.3%	-$3.6M-7.9%	-$3.4M-78.8%	-$1.9M+15.4%	-$2.2M+33.2%	-$3.3M+44.4%	-$6.0M
Financing Cash Flow	-$10.2M-3444.1%	-$288K+86.0%	-$2.1M-106.1%	$33.6M+2048.4%	-$1.7M+33.8%	-$2.6M-46.8%	-$1.8M-23.6%	-$1.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ORGO Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	76.0%+0.6pp	75.4%-1.3pp	76.7%+1.1pp	75.6%+1.4pp	74.2%+3.3pp	70.9%
Operating Margin	-0.3%-3.2pp	2.9%-2.1pp	5.0%-10.5pp	15.4%+7.6pp	7.9%+19.3pp	-11.4%
Net Margin	0.2%-1.0pp	1.1%-2.3pp	3.4%-16.7pp	20.2%+15.1pp	5.1%+19.9pp	-14.8%
Return on Equity	0.3%-1.4pp	1.8%-4.1pp	5.9%-33.2pp	39.0%+26.9pp	12.2%	N/A
Return on Assets	0.2%-0.9pp	1.1%-2.4pp	3.5%-17.8pp	21.3%+15.3pp	5.9%+23.5pp	-17.5%
Current Ratio	3.69+0.9	2.80-0.2	2.97+0.2	2.74+0.2	2.56+0.5	2.10
Debt-to-Equity	0.89+0.7	0.24-0.0	0.27-0.0	0.31-0.2	0.49-0.5	0.95
FCF Margin	0.9%-0.6pp	1.5%+3.5pp	-2.0%-8.6pp	6.6%+10.2pp	-3.6%+11.5pp	-15.1%

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	72.6%-2.8pp	75.5%-2.1pp	77.6%+3.7pp	73.9%+1.8pp	72.1%-4.1pp	76.2%
Operating Margin	13.7%+26.2pp	-12.4%+18.4pp	-30.9%-38.9pp	8.1%+18.7pp	-10.7%-7.2pp	-3.5%-2.2pp	-1.3%-8.7pp	7.4%
Net Margin	14.3%+23.6pp	-9.3%+12.4pp	-21.7%-27.8pp	6.1%+19.1pp	-13.1%-11.2pp	-1.9%-1.3pp	-0.6%-3.5pp	2.9%
Return on Equity	8.5%	N/A	N/A	2.9%	N/A	N/A	N/A	1.1%
Return on Assets	4.2%+6.3pp	-2.0%+2.0pp	-4.0%-5.6pp	1.5%+5.4pp	-3.9%-3.4pp	-0.5%-0.3pp	-0.1%-0.8pp	0.7%
Current Ratio	3.32-0.6	3.95-0.2	4.12+0.4	3.69+1.0	2.73-0.0	2.74-0.1	2.80+0.0	2.77
Debt-to-Equity	1.00+0.0	0.98+0.1	0.92+0.0	0.89+0.7	0.240.0	0.230.0	0.240.0	0.25
FCF Margin	0.6%+36.7pp	-36.1%-9.0pp	-27.2%-33.2pp	6.0%+3.8pp	2.2%+13.5pp	-11.3%-18.6pp	7.3%-2.6pp	9.9%

Similar Companies

Siga Technologie SIGA

$478.4M

Aquestive Therapeutics AQST

$467.3M

Akebia Therapeut AKBA

$313.1M

Esperion Therape ESPR

$853.5M

Evolus EOLS

$281.3M

Frequently Asked Questions

What is Organogenesis Hldgs Inc's annual revenue?

Organogenesis Hldgs Inc (ORGO) reported $482.0M in total revenue for fiscal year 2024. This represents a 11.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Organogenesis Hldgs Inc's revenue growing?

Organogenesis Hldgs Inc (ORGO) revenue grew by 11.3% year-over-year, from $433.1M to $482.0M in fiscal year 2024.

Is Organogenesis Hldgs Inc profitable?

Yes, Organogenesis Hldgs Inc (ORGO) reported a net income of $861K in fiscal year 2024, with a net profit margin of 0.2%.

What is Organogenesis Hldgs Inc's earnings per share (EPS)?

Organogenesis Hldgs Inc (ORGO) reported diluted earnings per share of $-0.01 for fiscal year 2024. This represents a -125.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Organogenesis Hldgs Inc's EBITDA?

Organogenesis Hldgs Inc (ORGO) had EBITDA of $12.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Organogenesis Hldgs Inc's gross margin?

Organogenesis Hldgs Inc (ORGO) had a gross margin of 76.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Organogenesis Hldgs Inc's operating margin?

Organogenesis Hldgs Inc (ORGO) had an operating margin of -0.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Organogenesis Hldgs Inc's net profit margin?

Organogenesis Hldgs Inc (ORGO) had a net profit margin of 0.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Organogenesis Hldgs Inc's return on equity (ROE)?

Organogenesis Hldgs Inc (ORGO) has a return on equity of 0.3% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Organogenesis Hldgs Inc's free cash flow?

Organogenesis Hldgs Inc (ORGO) generated $4.2M in free cash flow during fiscal year 2024. This represents a -36.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Organogenesis Hldgs Inc's operating cash flow?

Organogenesis Hldgs Inc (ORGO) generated $14.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Organogenesis Hldgs Inc's total assets?

Organogenesis Hldgs Inc (ORGO) had $497.9M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Organogenesis Hldgs Inc's capital expenditures?

Organogenesis Hldgs Inc (ORGO) invested $10.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Organogenesis Hldgs Inc spend on research and development?

Organogenesis Hldgs Inc (ORGO) invested $50.3M in research and development during fiscal year 2024.

Does Organogenesis Hldgs Inc buy back shares?

Yes, Organogenesis Hldgs Inc (ORGO) spent $25.5M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

How many shares does Organogenesis Hldgs Inc have outstanding?

Organogenesis Hldgs Inc (ORGO) had 126M shares outstanding as of fiscal year 2024.

What is Organogenesis Hldgs Inc's current ratio?

Organogenesis Hldgs Inc (ORGO) had a current ratio of 3.69 as of fiscal year 2024, which is generally considered healthy.

What is Organogenesis Hldgs Inc's debt-to-equity ratio?

Organogenesis Hldgs Inc (ORGO) had a debt-to-equity ratio of 0.89 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Organogenesis Hldgs Inc's return on assets (ROA)?

Organogenesis Hldgs Inc (ORGO) had a return on assets of 0.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Organogenesis Hldgs Inc's Piotroski F-Score?

Organogenesis Hldgs Inc (ORGO) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Organogenesis Hldgs Inc's earnings high quality?

Organogenesis Hldgs Inc (ORGO) has an earnings quality ratio of 16.50x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Organogenesis Hldgs Inc cover its interest payments?

Organogenesis Hldgs Inc (ORGO) has an interest coverage ratio of -0.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Organogenesis Hldgs Inc?

Organogenesis Hldgs Inc (ORGO) scores 41 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.